Analytical Data
-
Gene name
GRIN2D
- Application
-
Alternative Names
EB11; NMDAR2D; NR2D; N-Methyl-d-Aspartate Receptor Subunit 2D; Glutamate [NMDA] receptor subunit epsilon-4
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15399
-
Expression Region
Phe28~Ala584
-
Molecular Weight
64kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GRIN2D gene encodes for a subunit of the NMDA receptor, a critical player in synaptic plasticity and neurotransmission in the central nervous system. Recent research highlights the importance of NMDA receptors in various neurological disorders, such as schizophrenia, Alzheimer's disease, and epilepsy, making GRIN2D an intriguing target for therapeutic intervention. Despite its significance, the functional properties and molecular mechanisms of the GRIN2D subunit remain poorly understood compared to its well-studied counterparts. To address this gap, researchers have turned to the production of recombinant GRIN2D proteins to facilitate in-depth studies of its pharmacological characteristics, protein interactions, and role in receptor assembly and function. Utilizing advanced techniques in recombinant DNA technology, scientists aim to express and purify GRIN2D proteins for structural and functional analyses. Such studies are essential for elucidating the nuances of NMDA receptor signaling and for developing targeted therapies that could ameliorate the effects of disorders linked to dysfunctional GRIN2D pathways. As research progresses, a deeper understanding of GRIN2D's role in neurobiology may uncover new avenues for drug discovery and therapeutic strategies.
